Recent 8-K filings for CPHI
Highest-materiality recent filing
China Pharma terminates auditor BF Borgers after SEC denies its practice privilege; appoints Enrome LLP
- SEC issued Rule 102(e) Order against BF Borgers CPA PC on May 3, 2024, barring it from appearing or practicing before the SEC as an accountant.
- China Pharma terminated Borgers as independent auditor on May 7, 2024, with audit committee approval.
-
CPHI subsidiary acquires patent for $6.93M via stock; issues 12.6M shares
Hainan Helpson acquires patent for Prinsepia Utilis Esterol Sublingual Tablets from Xiaoyan Zhang.
-
China Pharma subsidiary acquires Ipragliflozin patent for $9.8M in stock
Hainan Helpson enters Technology Transfer Agreement to acquire Ipragliflozin tablet patent from Juan Zhang.
-
China Pharma subsidiary to acquire captopril microcapsule patent for $6.3M in stock
Hainan Helpson subsidiary to receive Captopril microcapsule invention patent and preparation method from Lijie Tang.
-
China Pharma rescinds Dec 12 securities purchase agreement; deal void ab initio
On Dec 23, 2024, company and an unnamed investor agreed to rescind the Dec 12 securities purchase agreement.
-
SEC issued Rule 102(e) Order against BF Borgers CPA PC on May 3, 2024, barring it from appearing or practicing before the SEC as an accountant.
Materiality & sentiment trend
Max materiality 0.75 · Median 0.55 · Most common event other_material